Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial, and Wall Street is suddenly a bit less euphoric about the stock. On December 3, Morgan Stanley cut Regeneron from Overweight to Equal Weight with a $767 price target, arguing that the shares now more or less reflect fair value and that future upside will depend on how clearly the company can execute on its pipeline. MarketScreener+1 At the same